Palvella Therapeutics (NASDAQ:PVLA) Stock Price Target Raised at Oppenheimer

by · The Markets Daily

Palvella Therapeutics (NASDAQ:PVLA – Free Report) had its price objective lifted by Oppenheimer from $210.00 to $232.00 in a research report released on Friday,Benzinga reports. The firm currently has an outperform rating on the stock.

PVLA has been the subject of a number of other reports. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. William Blair assumed coverage on shares of Palvella Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Raymond James Financial set a $226.00 target price on shares of Palvella Therapeutics in a research note on Friday, October 16th. Chardan Capital reiterated a “buy” rating and set a $240.00 price target on shares of Palvella Therapeutics in a report on Wednesday, October 28th. Finally, Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $213.00.

View Our Latest Stock Analysis on Palvella Therapeutics

Palvella Therapeutics Price Performance

NASDAQ:PVLA traded up $19.07 during trading hours on Friday, hitting $175.92. The company’s stock had a trading volume of 502,014 shares, compared to its average volume of 237,190. The stock has a fifty day simple moving average of $142.54 and a 200-day simple moving average of $128.12. The company has a market capitalization of $2.54 billion, a P/E ratio of -31.99 and a beta of -0.21. Palvella Therapeutics has a twelve month low of $72.22 and a twelve month high of $176.94.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, topping the consensus estimate of ($1.78) by $0.08. On average, equities analysts predict that Palvella Therapeutics will post -6.39 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director George M. Jenkins sold 7,174 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total value of $935,202.64. Following the sale, the director owned 139,790 shares of the company’s stock, valued at $18,223,024.40. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kathleen Goin sold 4,313 shares of the business’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total transaction of $537,313.54. Following the completion of the sale, the chief operating officer directly owned 2,165 shares in the company, valued at approximately $269,715.70. This represents a 66.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 61,056 shares of company stock valued at $8,756,946 in the last ninety days. 17.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Palvella Therapeutics during the second quarter worth about $140,343,000. First Light Asset Management LLC boosted its holdings in Palvella Therapeutics by 38.3% in the first quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock valued at $122,251,000 after acquiring an additional 271,617 shares during the last quarter. Jennison Associates LLC increased its position in Palvella Therapeutics by 65.3% during the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock valued at $79,852,000 after purchasing an additional 253,128 shares during the period. Primecap Management Co. CA acquired a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $39,150,000. Finally, Siren L.L.C. increased its position in Palvella Therapeutics by 243.3% during the 1st quarter. Siren L.L.C. now owns 257,485 shares of the company’s stock valued at $32,096,000 after purchasing an additional 182,485 shares during the period. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.

Further Reading